• 1. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 2. An aquatic host–guest complex between a supramolecular G-quadruplex and the anticancer drug doxorubicin?
  José M. Rivera,Mariana Martín-Hidalgo,Jean C. Rivera-Ríos Org. Biomol. Chem., 2012,10, 7562-7565
• 3. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 4. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 5. An insight into the role of side chains in the microstructure and carrier mobility of high-performance conjugated polymers?
  Jianyao Huang,Dong Gao,Zhihui Chen,Weifeng Zhang Polym. Chem., 2021,12, 2471-2480

Recent Advances in the Application of 2,4-Dichloro-6-(trifluoromethyl)pyrimidine-5-carboxylic Acid (CAS: 887626-24-6) in Chemical Biology and Pharmaceutical Research

The compound 2,4-dichloro-6-(trifluoromethyl)pyrimidine-5-carboxylic acid (CAS: 887626-24-6) has recently emerged as a key intermediate in pharmaceutical synthesis and chemical biology research. This trifluoromethyl-substituted pyrimidine derivative has attracted significant attention due to its versatile reactivity profile and potential applications in drug discovery. Recent studies have demonstrated its utility as a building block for the synthesis of various biologically active molecules, particularly in the development of kinase inhibitors and antimicrobial agents.

Structural analyses reveal that the presence of both electron-withdrawing groups (chloro and trifluoromethyl substituents) and the carboxylic acid functionality at the 5-position make this compound particularly valuable for further derivatization. The trifluoromethyl group enhances metabolic stability and membrane permeability, while the carboxylic acid allows for straightforward conjugation to other molecular scaffolds. These properties have been exploited in several recent drug discovery programs targeting infectious diseases and cancer.

In synthetic methodology development, researchers have reported novel palladium-catalyzed cross-coupling reactions using 887626-24-6 as a starting material. A 2023 study published in the Journal of Medicinal Chemistry demonstrated efficient Suzuki-Miyaura coupling at the 4-position, enabling the rapid generation of diverse compound libraries for high-throughput screening. The electron-deficient nature of the pyrimidine ring facilitates these metal-catalyzed transformations while maintaining excellent functional group tolerance.

Recent pharmacological investigations have focused on derivatives of 2,4-dichloro-6-(trifluoromethyl)pyrimidine-5-carboxylic acid as potential kinase inhibitors. Computational docking studies suggest that the planar pyrimidine core can effectively interact with the ATP-binding sites of various kinases. Several research groups have reported promising in vitro activity against CDK and JAK family kinases, with IC50 values in the low micromolar range. These findings were presented at the 2024 American Chemical Society National Meeting.

The antimicrobial potential of this compound scaffold has also been explored. A 2024 publication in Bioorganic & Medicinal Chemistry Letters described a series of amide derivatives showing potent activity against drug-resistant Gram-positive bacteria. The researchers attribute this activity to the compounds' ability to disrupt bacterial cell wall biosynthesis, as confirmed through mechanistic studies using fluorescence microscopy and proteomic analysis.

From a chemical biology perspective, 887626-24-6 has proven valuable as a molecular probe for studying protein-ligand interactions. The presence of multiple halogen atoms allows for straightforward incorporation of radioactive or fluorescent labels, making it useful for binding studies and cellular imaging applications. Recent work has employed this compound in the development of photoaffinity probes for target identification in phenotypic screening campaigns.

Process chemistry advancements have addressed previous challenges in the large-scale synthesis of 2,4-dichloro-6-(trifluoromethyl)pyrimidine-5-carboxylic acid. A continuous flow chemistry approach published in Organic Process Research & Development (2023) demonstrated significant improvements in yield (85% vs. 62% batch) and purity (>99% by HPLC) while reducing hazardous waste generation. This development is particularly important as pharmaceutical companies scale up production of derivatives for clinical evaluation.

Looking forward, the unique properties of this pyrimidine derivative suggest continued utility in drug discovery. Current research directions include exploration of its use in PROTAC (proteolysis targeting chimera) design and as a fragment in DNA-encoded library technology. The compound's balance of synthetic accessibility and three-dimensional character makes it particularly attractive for these emerging approaches in chemical biology and medicinal chemistry.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)